Global Vulvovaginal Candidiasis Treatment Market size was valued at USD 1352.80 Million in 2022 and the total Vulvovaginal Candidiasis Treatment revenue is expected to grow at a CAGR of 5.25% from 2023 to 2029, reaching USD 1935.48 Million. Vulvovaginal Candidiasis (VVC) is primarily caused by Candida albicans, although other Candida species or yeasts are expected to occasionally be responsible. It is estimated that about 75% of women will experience at least one episode of VVC, and 40% to 45% will have recurrent episodes during their lifetime. Vulvovaginitis, which refers to an infection in the vulva and vagina in women, commonly occurs in their reproductive age. A smaller percentage, around 10% to 20% of women, may experience complicated VVC, necessitating specialized diagnostic and therapeutic approaches. As a result, this factor significantly impacted the Vulvovaginal Candidiasis Treatment market growth during the forecast period. The rising prevalence of Vulvovaginal Candidiasis among women, increasing risk of recurrent Vulvovaginal Candidiasis, driving the demand for new therapeutics for treatment, augmenting the Vulvovaginal Candidiasis treatment market's growth. In addition, the growing awareness of candidiasis infection among the target population and rising product innovation all across the world to cure candidiasis are expected to be the further factors driving the demand for new therapeutics. For instance, in September 2021, Cidara Therapeutics, Inc., presented new clinical and non-clinical data for its Rezafungin which is being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. Hence, such product innovation is expected to boost the Vulvovaginal Candidiasis treatment market growth.To know about the Research Methodology :- Request Free Sample Report
Vulvovaginal Candidiasis Treatment Market Dynamics:
Increasing prevalence of Vulvovaginal candidiasis (VVC) The increasing prevalence of VVC among women is expected to be the primary factor driving the vulvovaginal candidiasis treatment market growth. According to the MMR analysis, it is estimated that more than 75% of women throughout their reproductive age have a minimum of one episode/ circumstance of vulvovaginal candidiasis (VVC) and approximately half of the women have two or more episodes/occurrences. Approximately 138 million women all across the world are expected to affect by recurrent vulvovaginal candidiasis each year, resulting in a global prevalence of 3871 cases per 100,000 women. As a result, improved treatment solutions to treat the conditions are on the rise due to the high prevalence rate of this condition, significant morbidity, and monetary costs of recurrent vulvovaginal candidiasis. 10% to 20% of women are expected to have complex VVC, necessitating specific diagnostic and treatment considerations. As a result, the increasing prevalence of vulvovaginal candidiasis among women is rising the demand for advanced treatment solutions such as oral and topical antifungal medications, thus driving the revenue growth of the vulvovaginal candidiasis treatment market throughout the forecast period.Rising regulatory approvals The rising regulatory approvals for the treatment of vulvovaginal candidiasis are expected to offer lucrative growth potentials for the vulvovaginal candidiasis treatment market players during the forecast period. Topical medications for the vulvovaginal candidiasis treatment have experienced a notable increase in regulatory approvals by various authorities such as the U.S. Food and Drug Administration (FDA), etc. according to the analysis, currently, the FDA has approved medications designed to address Mycovia, a pharmaceutical company specializing in antifungal treatments. These approved medications include oteseconazole, which is the first product from Mycovia to receive FDA approval. Oteseconazole is categorized as an azole antifungal and is indicated for reducing the occurrence of Recurrent Vulvovaginal Candidiasis (RVVC). Additionally, ibrexafungerp tablets, marketed as Brexafemme, have also been approved by the FDA. Healthcare professionals commonly prescribe both oteseconazole and ibrexafungerp tablets (Brexafemme) for the treatment of vaginal yeast infections, including vulvovaginal candidiasis (VVC). These medications have gained significant popularity among medical practitioners for their effectiveness in addressing such infections.
Vulvovaginal Candidiasis Treatment Market Segment Analysis:
By type, the recurrent vulvovaginal candidiasis segment held the highest market share of over 45% and led the global vulvovaginal candidiasis treatment market in 2022. The segment is further expected to maintain its trends during the forecast period. Recurrent vulvovaginal candidiasis (RVVC) is a complicated form of vaginal yeast infection. It occurs in less than 5% of women but has a significant economic impact. Around 40-50% of VVC cases experience recurrent episodes. RVVC can be classified as idiopathic (with no known underlying causes) or secondary, which can be linked to factors like frequent antibiotic use, diabetes, or other host-related factors. The underlying mechanisms of RVVC are not well understood, and most women with RVVC do not have identifiable predisposing conditions. Non-albicans Candida species like C. glabrata are found in 10-20% of women with recurrent VVC. Recurrent VVC can be associated with coexisting dermatological conditions such as lichen sclerosis and immunosuppression like HIV infection. The increasing prevalence of RVVC, the need for prolonged treatments, growing awareness, and the development of effective drugs are expected to drive the growth of this segment. By drug class, the fluconazole segment dominated the global vulvovaginal candidiasis treatment market in 2022. Oral treatment with a single dose of fluconazole is effective for treating uncomplicated VVC. Treatment of complicated VVC is prolonged and most commonly consists of multiple doses of oral fluconazole. Thus increasing the need for fluconazole for treating VVC driving the segment growth. However, with the entry of BREXAFEMME and Mycovia in the space, Fluconazole's share is expected to decline by the end of the forecast period. Nevertheless, these novel drugs come with higher pricing, which could slow down their market penetration. Antimycotic agent, Clotrimazole, was first registered under the brand name Canesten in Germany in 1973. Canesten is still among the leading brand for the treatment of vulvovaginal candidiasis. Later, external cream, internal vaginal cream, and soft capsule (soft ovule) were available. The industry has the presence of different formulations under different trade names, such as Abzorb, Candid-V, Mycoderm-C, Surfaz, Kansel, Imidil, Orasep OT, and Cloben. By Route of Administration, the oral segment is expected to grow at a CAGR of 5.50% during the forecast period and hold the highest market share by 2029. The increasing prevalence of vaginal yeast infections, along with the rising awareness and diagnosis of the condition, is expected to increase the demand for effective treatment. Oral medicines are a common & convenient route of administration for azoles, with good bioavailability, and are increasingly used for anti-fungal drugs. As a result, these factors are expected to support the segment growth during the forecast period. Oral fluconazole is the most common prescription drug recommended as treatment and maintenance therapy. It is also effective as short-duration therapy in recurrent VVC cases. Recently, the FDA has approved two oral dosage regimes of VIVJOA (oteseconazole) to reduce incidences of recurrent VVC. Additionally, the convenience and effectiveness of oral medications contribute to their popularity among both patients and healthcare providers. The development and launch of more advanced and potent antifungal drugs further contribute to the growth of the segment and increase the revenue share of the vulvovaginal candidiasis treatment market during the forecast period.Vulvovaginal Candidiasis Treatment Market Regional Insights:
North America led the global vulvovaginal candidiasis treatment market with the highest revenue share of over 40% in 2022. The region is expected to maintain its trends throughout the forecast period. The increasing target population of vulvovaginal candidiasis across the region is expected to be the primary growth factor driving the regional market growth. In addition, increasing awareness regarding vulvovaginal candidiasis among women, rising healthcare expenditures, availability of advanced therapeutic options, etc. are further contributing to the market growth. The rising clinical trials and research and development activities in North America are expected to support the vulvovaginal candidiasis treatment market revenue growth. For example, In June 2021, the FDA granted authorization to BREXAFEMME, primarily for treating Vulvovaginal Candidiasis (VVC). On November 2022, the FDA approved its secondary use for preventing recurrent VVC. Additionally, ongoing late-stage clinical trials are investigating Ibrexafungerp's effectiveness in treating severe invasive fungal infections in hospitalized patients. The U.S. is expected to lead the regional market by 2029 due to increasing research and product development activities, increasing patient population, governmental initiatives to increase awareness of the conditions, etc. According to the MMR analysis, around 149,934 women in the United States were diagnosed with Vulvovaginal Candidiasis (VVC) in April 2022, with 3.4% of them experiencing recurrent VVC (RVVC). The South census region had the highest VVC rate, standing at 14.3 cases per 1,000 female patients. This high prevalence of vaginal candidiasis is driving the demand for new therapeutics and contributing to the vulvovaginal candidiasis treatment market growth in the country.Vulvovaginal Candidiasis Treatment Market Scope: Inquire before buying
Vulvovaginal Candidiasis Treatment Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: USD 1352.80 Million Forecast Period 2023 to 2029 CAGR: 5.25 % Market Size in 2029: USD 1935.48 Million Segments Covered: by Type Acute Vulvovaginal Candidiasis Recurrent Vulvovaginal Candidiasis Severe Vulvovaginal Candidiasis Non–albicans Vulvovaginal Candidiasis by Drug Class Clotrimazole Nystatin Fluconazole Ketoconazole Terbinafine Terconazole Others by Route of Administration Oral Intravenous Topical by Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Vulvovaginal Candidiasis Treatment Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Vulvovaginal Candidiasis Treatment Market Key Players:
1. Astellas Pharma Inc. (Japan) 2. Mycovia Pharmaceuticals, Inc. (United States) 3. Basilea Pharmaceutica Ltd. (Switzerland) 4. Scynexis, Inc. (United States) 5. Grupo Ferrer Internacional S.A. (Spain) 6. Cadila Pharmaceuticals (India) 7. Bristol-Myers Squibb Company (United States) 8. Mylan N.V. (United States) 9. Lupin Limited (India) 10. Sun Pharmaceutical Industries Ltd. (India) 11. Glenmark Pharmaceuticals Ltd. (India) 12. Cipla Limited (India) 13. Dr. Reddy's Laboratories Ltd. (India) 14. Aurobindo Pharma Limited (India) 15. Torrent Pharmaceuticals Ltd. (India) 16. Zydus Cadila (India) 17. Alembic Pharmaceuticals Limited (India) 18. Sandoz International GmbH (Switzerland) 19. Accord Healthcare Ltd. (United Kingdom) 20. Amneal Pharmaceuticals LLC (United States) FAQs: 1. What are the growth drivers for the Vulvovaginal Candidiasis Treatment market? Ans. The rising prevalence of Vulvovaginal Candidiasis among women and the increasing risk of recurrent Vulvovaginal Candidiasis is expected to be the major driver for the Vulvovaginal Candidiasis Treatment market. 2. What is the major restraint for the Vulvovaginal Candidiasis Treatment market growth? Ans. Stringent government regulations are expected to be the major restraining factor for the Vulvovaginal Candidiasis Treatment market growth. 3. Which region is expected to lead the global Vulvovaginal Candidiasis Treatment market during the forecast period? Ans. North America is expected to lead the global Vulvovaginal Candidiasis Treatment market during the forecast period. 4. What is the projected market size & growth rate of the Vulvovaginal Candidiasis Treatment Market? Ans. The Global Vulvovaginal Candidiasis Treatment Market size was valued at USD 1352.80 Million in 2022 and the total Vulvovaginal Candidiasis Treatment revenue is expected to grow at a CAGR of 5.25% from 2023 to 2029, reaching nearly USD 1935.48 Million. 5. What segments are covered in the Vulvovaginal Candidiasis Treatment Market report? Ans. The segments covered in the Vulvovaginal Candidiasis Treatment market report are Type, Drug Class, Route of Administration, Distribution Channel, and Region.
1. Vulvovaginal Candidiasis Treatment Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Vulvovaginal Candidiasis Treatment Market: Dynamics 2.1. Vulvovaginal Candidiasis Treatment Market Trends by Region 2.1.1. North America Vulvovaginal Candidiasis Treatment Market Trends 2.1.2. Europe Vulvovaginal Candidiasis Treatment Market Trends 2.1.3. Asia Pacific Vulvovaginal Candidiasis Treatment Market Trends 2.1.4. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Trends 2.1.5. South America Vulvovaginal Candidiasis Treatment Market Trends 2.2. Vulvovaginal Candidiasis Treatment Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Vulvovaginal Candidiasis Treatment Market Drivers 2.2.1.2. North America Vulvovaginal Candidiasis Treatment Market Restraints 2.2.1.3. North America Vulvovaginal Candidiasis Treatment Market Opportunities 2.2.1.4. North America Vulvovaginal Candidiasis Treatment Market Challenges 2.2.2. Europe 2.2.2.1. Europe Vulvovaginal Candidiasis Treatment Market Drivers 2.2.2.2. Europe Vulvovaginal Candidiasis Treatment Market Restraints 2.2.2.3. Europe Vulvovaginal Candidiasis Treatment Market Opportunities 2.2.2.4. Europe Vulvovaginal Candidiasis Treatment Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Vulvovaginal Candidiasis Treatment Market Drivers 2.2.3.2. Asia Pacific Vulvovaginal Candidiasis Treatment Market Restraints 2.2.3.3. Asia Pacific Vulvovaginal Candidiasis Treatment Market Opportunities 2.2.3.4. Asia Pacific Vulvovaginal Candidiasis Treatment Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Drivers 2.2.4.2. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Restraints 2.2.4.3. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Opportunities 2.2.4.4. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Challenges 2.2.5. South America 2.2.5.1. South America Vulvovaginal Candidiasis Treatment Market Drivers 2.2.5.2. South America Vulvovaginal Candidiasis Treatment Market Restraints 2.2.5.3. South America Vulvovaginal Candidiasis Treatment Market Opportunities 2.2.5.4. South America Vulvovaginal Candidiasis Treatment Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Vulvovaginal Candidiasis Treatment Industry 2.8. Analysis of Government Schemes and Initiatives For Vulvovaginal Candidiasis Treatment Industry 2.9. Vulvovaginal Candidiasis Treatment Market Trade Analysis 2.10. The Global Pandemic Impact on Vulvovaginal Candidiasis Treatment Market 3. Vulvovaginal Candidiasis Treatment Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 3.1.1. Acute Vulvovaginal Candidiasis 3.1.2. Recurrent Vulvovaginal Candidiasis 3.1.3. Severe Vulvovaginal Candidiasis 3.1.4. Non–albicans Vulvovaginal Candidiasis 3.2. Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 3.2.1. Clotrimazole 3.2.2. Nystatin 3.2.3. Fluconazole 3.2.4. Ketoconazole 3.2.5. Terbinafine 3.2.6. Terconazole 3.2.7. Others 3.3. Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 3.3.1. Oral 3.3.2. Intravenous 3.3.3. Topical 3.4. Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 3.4.1. Hospital Pharmacy 3.4.2. Retail Pharmacy 3.4.3. Online Pharmacy 3.5. Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Region (2022-2029) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 4.1.1. Acute Vulvovaginal Candidiasis 4.1.2. Recurrent Vulvovaginal Candidiasis 4.1.3. Severe Vulvovaginal Candidiasis 4.1.4. Non–albicans Vulvovaginal Candidiasis 4.2. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 4.2.1. Clotrimazole 4.2.2. Nystatin 4.2.3. Fluconazole 4.2.4. Ketoconazole 4.2.5. Terbinafine 4.2.6. Terconazole 4.2.7. Others 4.3. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.3.1. Oral 4.3.2. Intravenous 4.3.3. Topical 4.4. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 4.4.1. Hospital Pharmacy 4.4.2. Retail Pharmacy 4.4.3. Online Pharmacy 4.5. North America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Country (2022-2029) 4.5.1. United States 4.5.1.1. United States Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 4.5.1.1.1. Acute Vulvovaginal Candidiasis 4.5.1.1.2. Recurrent Vulvovaginal Candidiasis 4.5.1.1.3. Severe Vulvovaginal Candidiasis 4.5.1.1.4. Non–albicans Vulvovaginal Candidiasis 4.5.1.2. United States Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 4.5.1.2.1. Clotrimazole 4.5.1.2.2. Nystatin 4.5.1.2.3. Fluconazole 4.5.1.2.4. Ketoconazole 4.5.1.2.5. Terbinafine 4.5.1.2.6. Terconazole 4.5.1.2.7. Others 4.5.1.3. United States Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.5.1.3.1. Oral 4.5.1.3.2. Intravenous 4.5.1.3.3. Topical 4.5.1.4. United States Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 4.5.1.4.1. Hospital Pharmacy 4.5.1.4.2. Retail Pharmacy 4.5.1.4.3. Online Pharmacy 4.5.2. Canada 4.5.2.1. Canada Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 4.5.2.1.1. Acute Vulvovaginal Candidiasis 4.5.2.1.2. Recurrent Vulvovaginal Candidiasis 4.5.2.1.3. Severe Vulvovaginal Candidiasis 4.5.2.1.4. Non–albicans Vulvovaginal Candidiasis 4.5.2.2. Canada Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 4.5.2.2.1. Clotrimazole 4.5.2.2.2. Nystatin 4.5.2.2.3. Fluconazole 4.5.2.2.4. Ketoconazole 4.5.2.2.5. Terbinafine 4.5.2.2.6. Terconazole 4.5.2.2.7. Others 4.5.2.3. Canada Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.5.2.3.1. Oral 4.5.2.3.2. Intravenous 4.5.2.3.3. Topical 4.5.2.4. Canada Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 4.5.2.4.1. Hospital Pharmacy 4.5.2.4.2. Retail Pharmacy 4.5.2.4.3. Online Pharmacy 4.5.3. Mexico 4.5.3.1. Mexico Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 4.5.3.1.1. Acute Vulvovaginal Candidiasis 4.5.3.1.2. Recurrent Vulvovaginal Candidiasis 4.5.3.1.3. Severe Vulvovaginal Candidiasis 4.5.3.1.4. Non–albicans Vulvovaginal Candidiasis 4.5.3.2. Mexico Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 4.5.3.2.1. Clotrimazole 4.5.3.2.2. Nystatin 4.5.3.2.3. Fluconazole 4.5.3.2.4. Ketoconazole 4.5.3.2.5. Terbinafine 4.5.3.2.6. Terconazole 4.5.3.2.7. Others 4.5.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.5.3.3.1. Oral 4.5.3.3.2. Intravenous 4.5.3.3.3. Topical 4.5.3.4. Mexico Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 4.5.3.4.1. Hospital Pharmacy 4.5.3.4.2. Retail Pharmacy 4.5.3.4.3. Online Pharmacy 5. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.1. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.1. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.1. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5. Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Country (2022-2029) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.1.2. United Kingdom Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.1.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.1.4. United Kingdom Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.2. France 5.5.2.1. France Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.2.2. France Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.2.3. France Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.2.4. France Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.3. Germany 5.5.3.1. Germany Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.3.2. Germany Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.3.3. Germany Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.3.4. Germany Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.4. Italy 5.5.4.1. Italy Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.4.2. Italy Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.4.3. Italy Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.4.4. Italy Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.5. Spain 5.5.5.1. Spain Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.5.2. Spain Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.5.3. Spain Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.5.4. Spain Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.6. Sweden 5.5.6.1. Sweden Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.6.2. Sweden Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.6.3. Sweden Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.6.4. Sweden Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.7. Austria 5.5.7.1. Austria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.7.2. Austria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.7.3. Austria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.7.4. Austria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 5.5.8.2. Rest of Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 5.5.8.3. Rest of Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.5.8.4. Rest of Europe Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.2. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.3. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.4. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5. Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Country (2022-2029) 6.5.1. China 6.5.1.1. China Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.1.2. China Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.1.3. China Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.1.4. China Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.2. S Korea 6.5.2.1. S Korea Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.2.2. S Korea Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.2.3. S Korea Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.2.4. S Korea Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.3. Japan 6.5.3.1. Japan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.3.2. Japan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.3.3. Japan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.3.4. Japan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.4. India 6.5.4.1. India Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.4.2. India Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.4.3. India Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.4.4. India Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.5. Australia 6.5.5.1. Australia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.5.2. Australia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.5.3. Australia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.5.4. Australia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.6. Indonesia 6.5.6.1. Indonesia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.6.2. Indonesia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.6.3. Indonesia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.6.4. Indonesia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.7. Malaysia 6.5.7.1. Malaysia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.7.2. Malaysia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.7.3. Malaysia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.7.4. Malaysia Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.8. Vietnam 6.5.8.1. Vietnam Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.8.2. Vietnam Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.8.3. Vietnam Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.8.4. Vietnam Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.9. Taiwan 6.5.9.1. Taiwan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.9.2. Taiwan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.9.3. Taiwan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.9.4. Taiwan Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 6.5.10.2. Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 6.5.10.3. Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.5.10.4. Rest of Asia Pacific Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 7. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 7.2. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 7.3. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.4. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 7.5. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Country (2022-2029) 7.5.1. South Africa 7.5.1.1. South Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 7.5.1.2. South Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 7.5.1.3. South Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.5.1.4. South Africa Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 7.5.2. GCC 7.5.2.1. GCC Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 7.5.2.2. GCC Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 7.5.2.3. GCC Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.5.2.4. GCC Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 7.5.3. Nigeria 7.5.3.1. Nigeria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 7.5.3.2. Nigeria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 7.5.3.3. Nigeria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.5.3.4. Nigeria Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 7.5.4.2. Rest of ME&A Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 7.5.4.3. Rest of ME&A Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.5.4.4. Rest of ME&A Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 8. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 8.2. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 8.3. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration(2022-2029) 8.4. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 8.5. South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Country (2022-2029) 8.5.1. Brazil 8.5.1.1. Brazil Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 8.5.1.2. Brazil Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 8.5.1.3. Brazil Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.5.1.4. Brazil Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 8.5.2. Argentina 8.5.2.1. Argentina Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 8.5.2.2. Argentina Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 8.5.2.3. Argentina Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.5.2.4. Argentina Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Type (2022-2029) 8.5.3.2. Rest Of South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Drug Class (2022-2029) 8.5.3.3. Rest Of South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.5.3.4. Rest Of South America Vulvovaginal Candidiasis Treatment Market Size and Forecast, by Distribution Channel (2022-2029) 9. Global Vulvovaginal Candidiasis Treatment Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Vulvovaginal Candidiasis Treatment Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Astellas Pharma Inc. (Japan) 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Mycovia Pharmaceuticals, Inc. (United States) 10.3. Basilea Pharmaceutica Ltd. (Switzerland) 10.4. Scynexis, Inc. (United States) 10.5. Grupo Ferrer Internacional S.A. (Spain) 10.6. Cadila Pharmaceuticals (India) 10.7. Bristol-Myers Squibb Company (United States) 10.8. Mylan N.V. (United States) 10.9. Lupin Limited (India) 10.10. Sun Pharmaceutical Industries Ltd. (India) 10.11. Glenmark Pharmaceuticals Ltd. (India) 10.12. Cipla Limited (India) 10.13. Dr. Reddy's Laboratories Ltd. (India) 10.14. Aurobindo Pharma Limited (India) 10.15. Torrent Pharmaceuticals Ltd. (India) 10.16. Zydus Cadila (India) 10.17. Alembic Pharmaceuticals Limited (India) 10.18. Sandoz International GmbH (Switzerland) 10.19. Accord Healthcare Ltd. (United Kingdom) 10.20. Amneal Pharmaceuticals LLC (United States) 11. Key Findings 12. Industry Recommendations 13. Vulvovaginal Candidiasis Treatment Market: Research Methodology 14. Terms and Glossary